T vs. C | regorafenib | BSC | atezolizumab alone | durvalumab plus tremelimumab | atezolizumab plus cometinib |
regorafenib | --- | NA | NA | NA | NA |
BSC | NA | --- | NA | NA | NA |
atezolizumab alone | NA | NA | --- | NA | NA |
durvalumab plus tremelimumab | NA | NA | NA | --- | NA |
atezolizumab plus cometinib | NA | NA | NA | NA | --- |
pathologies: 138
- treatments: 696
result logic